Dr. Janet Englund
Pediatric Infectious Disease (Pediatric Infectious Diseases Physician)
4800 Sand Point Way Ne
Seattle, WA 98105
Who else practices at this address →
King County includes primary care (5% of residents) and dental (4% of residents) and mental health (4% of residents) shortage areas. About shortage areas
At a glance
- In the NPI registry since
- 2006
Licensed in Washington since 2002, according to the Washington State Department of Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Infectious Diseases Physician primary
WA license MD00041589 (first issued 2002; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 8 companies reported 24 payments worth $90,474 in total to this clinician.
| ModernaTX, Inc. | $35,128 |
|---|---|
| Merck Sharp & Dohme LLC | $13,140 |
| Pfizer International LLC | $10,942 |
| Shionogi Inc | $9,440 |
| Pfizer Inc. | $8,500 |
| GlaxoSmithKline, LLC. | $6,175 |
| AstraZeneca UK Limited | $4,950 |
| AstraZeneca Pharmaceuticals LP | $2,200 |
| Consulting Fee | $77,993 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $10,875 |
| Travel and Lodging | $1,420 |
| Food and Beverage | $187 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| ModernaTX, Inc. Feb 25, 2025 | Consulting Fee | $29,828 |
| Pfizer International LLC Jan 23, 2025 | Compensation for services other than consulting (speaking, faculty) COMIRNATY · VACCINES | $10,875 |
| Shionogi Inc Sep 19, 2025 | Consulting Fee S-337395 · Infections and Infectious Diseases | $9,440 |
| Pfizer Inc. Oct 30, 2025 | Consulting Fee COMIRNATY · VACCINES | $7,500 |
| ModernaTX, Inc. Sep 24, 2025 | Consulting Fee | $5,300 |
| Merck Sharp & Dohme LLC Apr 1, 2025 | Consulting FeeCompany’s descriptionProvided as part of a research engagement. | $5,220 |
| AstraZeneca UK Limited Mar 19, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $4,950 |
| Merck Sharp & Dohme LLC Mar 24, 2025 | Consulting Fee | $3,770 |
| Merck Sharp & Dohme LLC Nov 10, 2025 | Consulting Fee ENFLONSIA · INFECTIOUS DISEASE Company’s descriptionProvided as part of a clinical research engagement. | $2,610 |
| GlaxoSmithKline, LLC. Apr 25, 2025 | Consulting Fee | $2,600 |
All 19 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Nov 10, 2025 | Consulting Fee ENFLONSIA · INFECTIOUS DISEASE Company’s descriptionProvided as part of a clinical research engagement. | $2,610 |
| Pfizer Inc. Oct 30, 2025 | Consulting Fee COMIRNATY · VACCINES | $7,500 |
| Pfizer Inc. Oct 30, 2025 | Consulting Fee COMIRNATY · VACCINES | $1,000 |
| ModernaTX, Inc. Sep 24, 2025 | Consulting Fee | $5,300 |
| Shionogi Inc Sep 19, 2025 | Consulting Fee S-337395 · Infections and Infectious Diseases | $9,440 |
| GlaxoSmithKline, LLC. May 8, 2025 | Consulting Fee | $2,600 |
| GlaxoSmithKline, LLC. May 7, 2025 | Consulting Fee | $975 |
| GlaxoSmithKline, LLC. Apr 25, 2025 | Consulting Fee | $2,600 |
| Pfizer International LLC Apr 10, 2025 | Travel and Lodging COMIRNATY · VACCINES · travel to CANCUN, Mexico · in-kind | $67.01 |
| Merck Sharp & Dohme LLC Apr 7, 2025 | Travel and Lodging travel to North Wales, PA Company’s descriptionProvided as part of a research engagement. | $346 |
| Merck Sharp & Dohme LLC Apr 1, 2025 | Consulting FeeCompany’s descriptionProvided as part of a research engagement. | $5,220 |
| Merck Sharp & Dohme LLC Mar 24, 2025 | Consulting Fee | $3,770 |
| Merck Sharp & Dohme LLC Mar 24, 2025 | Travel and Lodging travel to Iguazu Falls, Brazil | $150 |
| AstraZeneca UK Limited Mar 19, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $4,950 |
| ModernaTX, Inc. Feb 25, 2025 | Consulting Fee | $29,828 |
| Merck Sharp & Dohme LLC Feb 25, 2025 | Travel and Lodging travel to Upper Gwynedd, PA · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $186 |
| Merck Sharp & Dohme LLC Feb 24, 2025 | Travel and Lodging travel to Upper Gwynedd, PA · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $672 |
| AstraZeneca Pharmaceuticals LP Feb 13, 2025 | Consulting Fee FLUMIST QUADRIVALENT · Respiratory Company’s descriptionResearch Related Service | $2,200 |
| Pfizer International LLC Jan 23, 2025 | Compensation for services other than consulting (speaking, faculty) COMIRNATY · VACCINES | $10,875 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 3 companies. The companies reported $1,031,630 in research payments for these studies, mostly to the institutions running them.
- A master phase 123 protocol to investigate the safety tolerability and immunogenicity of bivalent BNT162B2 rna based vaccine candidates in healthy children
Pfizer Inc. - Uwashrsv seroepidemiology and antibody transfer among pregnant women and preterm infants
Pfizer Inc. - A phase 3 study to investigate the safety tolerability and immunogenicity of revaccinating pregnant participants during subsequent pregnancies and persistence of immunity of a single dose of a bivalent respiratory syn…
Pfizer Inc. - A Phase 2b open-label, single-arm trial to evaluate pharmacokinetics, efficacy, safety and tolerability of letermovir in pediatric participants from birth to less than 18 years of age at-risk of developing CMV infecti…
Merck Sharp & Dohme LLC - A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months
ModernaTX, Inc. · Active, not recruiting · NCT05743881 - A phase 3 randomized placebocontrolled doubleblinded trial to evaluate the safety tolerability and immunogenicity of a multivalent group b streptococcus vaccine in healthy pregnant women and their infants
Pfizer Inc. - A phase 3 protocol to investigate the safety tolerability and immunogenicity of a BNT162B2 LP81ADAPTED vaccine in children 5 through 11 years of age considered at high risk for severe COVID19
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.